Could hypertension possibly be adaptive?

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 2, 2010, Pages

  Prakash, Es ^a   Fink, Gd ^b  

^a AIMST UNIVERSITY   (Malaysia)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Autoregulation; Blood flow; Blood pressure; Homeostasis; Metaboreflex; Sympathetic nervous system

Indexed keywords

ANTIHYPERTENSIVE AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; CARDIOVASCULAR AUTOREGULATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; OBESITY; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; SMOKING; VASODILATATION;

ADULT; ANIMALS; CARDIOVASCULAR SYSTEM; DOGS; ENDOTHELIUM, VASCULAR; FEMALE; HOMEOSTASIS; HUMANS; HYPERTENSION; LONGEVITY; MIDDLE AGED; PREGNANCY; RATS; VASODILATION;

EID: 75649098983     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05284.x     Document Type: Review

References (88)

1. Kaplan NM. Kaplan's Clinical Hypertension. Lippincott, Williams & Wilkins, Philadelphia, 2002.
2. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood Pressure. Hypertension 2003 42 : 1206 1252.
3. Folkow B. Physiological aspects of primary hypertension. Physiol. Rev. 1982 62 : 347 504.
4. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 : 1903 1913.
5. Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. Lancet 2000 355 : 175 180.
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003 362 : 1527 1535.
7. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 2007 1 : CD002252.
8. Hall JE. The kidney, hypertension, and obesity hypertension. Hypertension 2003 41 : 625 633.
9. Osborn JW. Hypothesis: Set points and long-term control of arterial pressure. A theoretical argument for a long-term arterial pressure control system in the brain rather than the kidney. ClExp. Pharmacol. Physiol. 2005 32 : 384 393.
10. Grubb BP, Samoil D, Kosinski D et al. Cerebral syncope: Loss of consciousness associated with cerebral vasoconstriction in the absence of systemic hypotension. Pacing ClElectrophysiol. 1998 21 : 652 658.
11. Guyton AC. The body's approach to arterial pressure regulation. In : Guyton AC (ed.). Arterial Pressure and Hypertension. WB Saunders, Philadelphia, 1980 1 10.
12. Paton JFR, Dickinson CJ, Mitchell G. Harvey cushing and the regulation of blood pressure in giraffe, rat and man: Introducing 'Cushing's mechanism'. Exp. Physiol. 2008 94 : 11 17.
13. Wright JR, McCloskey DI, Fitzpatrick RC. Effects of systemic arterial blood pressure on the contractile force of a human hand muscle. J. Appl. Physiol. 2000 88 : 1390 1396.
14. Walker KL, Saunders NR, Jensen D et al. Do vasoregulatory mechanisms in exercising human muscle compensate for changes in arterial perfusion pressure? Am. J. Physiol. Heart Circ. Physiol. 2007 293 : H2928 36.
15. Smith SA, Mitchell JH, Garry MG. The mammalian exercise pressor reflex in health and disease. Exp. Physiol. 2005 91 : 89 102.
16. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc. Brain Metab. Rev. 1990 2 : 161 192.
17. Folkow B. Regulation of the peripheral circulation. Br. Heart J. 1971 33 : 27 31.
18. Victor RG, Bertocci LA, Pryor SL, Nunnally RL. Sympathetic nerve discharge is coupled to muscle cell pH during exercise in humans. J. ClInvest. 1988 82 : 1301 1305.
19. 2 delivery to ischemic active skeletal muscle. Am. J. Physiol. 1999 276 : H1399 403.
20. Fink GD. Hypothesis: The systemic circulation as a regulated free-market econom. A new approach for understanding the long-term control of blood pressure. ClExp. Pharmacol. Physiol. 2005 32 : 377 383.
21. Smith ML, Pacchia CF. Sleep apnoea and hypertension: Role of chemoreflexes in humans. Exp. Physiol. 2007 92 : 45 50.
22. Prabhakar NR, Dick TE, Nanduri J, Kumar GK. Sleep apnoea and hypertension: Physiological bases for a causal relation. Systemic, cellular and molecular analysis of chemoreflex-mediated sympathoexcitation by chronic intermittent hypoxia. Exp. Physiol. 2007 92 : 39 44.
23. Barlow CE, LaMonte MJ, Fitzgerald SJ, Kampert JB, Perrin JL, Blair SN. Cardiorespiratory fitness is an independent predictor of hypertension incidence among initially normotensive healthy women. Am. J. Epidemiol. 2006 163 : 142 150.
24. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: Functional markers. Circulation 2004 109 (Suppl. IV IV31 46.
25. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Robison J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993 88 : 2149 2155.
26. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano M. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006 47 : 45 50.
27. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity. The link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009 53 : 577 584.
28. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J. Am. Coll. Cardiol. 2003 41 : 1387 1393.
29. Kearney MT, Duncan ER, Kahn M, Wheatcroft SB. Insulin resistance and endothelial cell dysfunction: Studies in mammalian models. Exp. Physiol. 2007 93 : 158 163.
30. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. Testing and clinical relevance. Circulation 2007 115 : 1285 1295.
31. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 2003 42 : 1149 1160.
32. Landmesser U, Horning B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004 109 (Suppl.II II27 33.
33. Goligorsky MS. Endothelial cell dysfunction: Can't live with it, how to live without it. Am. J. Physiol. Renal Physiol. 2005 288 : 871 880.
34. Gamici PG, Crea F. Coronary microvascular dysfunction. N. Engl. J. Med. 2007 356 : 830 840.
35. Félétou M, Vanhoutte PM. Endothelial dysfunction: A multifaceted disorder (the Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 2006 291 : H985 1002.
36. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor-1. Physiology 2009 24 : 97 106.
37. Armour AJ. Myocardial ischaemia and the cardiac nervous system. Cardiovasc. Res. 1999 41 : 41 54.
38. Malliani A, Montano N. Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension 2002 39 : 63 8.
39. Stella A, Zanchetti A. Functional role of renal afferents. Physiol. Rev. 1991 71 : 659 682.
40. Brezis M, Rosen S. Hypoxia of the renal medulla: Its implications for disease. N. Engl. J. Med. 1995 332 : 647 655.
41. O'Connor PM. Renal oxygen delivery: Matching delivery to metabolic demand. ClExp. Pharmacol. Physiol. 2006 33 : 961 967.
42. Evans RG, Gardiner BS, Smith BW, O'Connor PM. Intrarenal oxygenation. Unique challenges and the biophysical basis of homeostasis. Am. J. Physiol. Renal Physiol. 2008 295 : F1259 70.
43. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995 25 : 878 882.
44. Philips JK. Pathogenesis of hypertension in chronic renal failure: Role of the sympathetic nervous system and renal afferents. ClExp. Pharmacol. Physiol. 2005 32 : 415 418.
45. Leal AK, Williams MA, Garry G, Mitchell JH, Smith SA. Evidence for functional alterations in the skeletal muscle mechanoreflex and metaboreflex in hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2008 295 : H1429 38.
46. Rondon MU, Laterza MC, deMatos LD et al. Abnormal muscle metaboreflex control of sympathetic activity in never-treated hypertensive subjects. Am. J. Hypertens. 2006 19 : 951 957.
47. Smith SA, Williams MA, Leal AK, Mitchell JH, Garry MG. Exercise pressor reflex function is altered in spontaneously hypertensive rats. J. Physiol. 2006 577 : 1009 1020.
48. Stahl GS, Longhurst JC. Ischemically sensitive visceral afferents. Importance of H+ derived from lactic acid and hypercapnia. Am. J. Physiol. 1992 262 : H748 53.
49. Xing J, Gao Z, Lu J, Sinoway LI, Li J. Femoral artery occlusion augments TRPV1-mediated sympathetic responsiveness. Am. J. Physiol. Heart Circ. Physiol. 2008 295 : H1262 9.
50. Zahner MR, Li DP, Chen SR, Pan HL. Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J. Physiol. 2003 551 : 515 523.
51. Pan HL, Chen SR. Sensing tissue ischemia: Another new function for capsaicin receptors? Circulation 2004 110 : 1826 1831.
52. Wang Y, Babánková D, Huang J, Swain GM, Wang DH. Deletion of transient receptor potential vanilloid type 1 receptors exaggerates renal damage in deoxycorticosterone acetate-salt hypertension. Hypertension 2008 52 : 264 270.
53. Guazzi M, Belletti S, Bianco E, Lenatti L, Guazzi MD. Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: Different results with cardioversion. Am. J. Physiol. Heart Circ. Physiol. 2006 291 : H921 8.
54. Guyton AC, Coleman TG, Cowley AW Jr., Manning RD Jr., Norman RA Jr., Ferguson FD. A systems analysis approach to understanding long-range arterial blood pressure control and hypertension. Circ. Res. 1974 35 : 159 176.
55. Folkow B. Resistance to blood flow at maximal vasodilatation. Hypertension 1988 12 : 635 637.
56. Korner PI. Circulatory regulation in hypertension. Br. J. ClPharmacol. 1982 13 : 95 105.
57. Taddei S, Virdis A, Mattei P et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997 29 : 736 743.
58. Levy BI, Schiffrin EL, Mourad JJ et al. Impaired tissue perfusion: A pathology common to hypertension, obesity and diabetes mellitus. Circulation 2008 118 : 968 976.
59. Vanhoutte PM. Ageing and endothelial dysfunction. Eur. Heart J. 2002 4 (Suppl. A A8 17.
60. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 1994 24 : 1468 1474.
61. Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RMA, Deanfield JE. Endothelium-dependent dilation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997 96 : 3378 3383.
62. Iellamo F, Tesauro M, Rizza S et al. Concomitant impairment in endothelial function and neural cardiovascular regulation in offspring of Type 2 diabetic subjects. Hypertension 2006 48 : 418 423.
63. Rodford JL, Torrens C, Siow RCM, Mann GE, Hanson MA, Clough GF. Endothelial dysfunction and reduced antioxidant protection in an animal model of the developmental origins of cardiovascular disease. J. Physiol. 2008 586 : 4709 4720.
64. Gelber RP, Gaziano JM, Manson JE, Buring JE, Sesso H. A prospective study of body mass index and the risk of developing hypertension in men. Am. J. Hypertens. 2007 20 : 370 377. (Pubitemid 46441762)
65. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. The san antonio heart study. Arch. Intern. Med. 1996 156 : 1994 2000.
66. Al Suwaidi J, Higano ST, Holmes DR Jr. et al. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J. Am. Coll. Cardiol. 2001 37 : 1523 1528.
67. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006 48 : 787 796.
68. Forman JP, Fisher NDL, Schopick EL, Curhan GC. Higher levels of albuminuria within the normal range predict incident hypertension. J. Am. Soc. Nephrol. 2008 19 : 1983 1988.
69. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001 104 : 191 196.
70. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008 294 : H541 50.
71. Greenwood JP, Scott EM, Stoker JB, Walker JJ, Mary DA. Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. Circulation 2001 104 : 2200 2204.
72. Liu VWT, Huang PL. Cardiovascular roles of nitric oxide: A review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res. 2008 77 : 19 29.
73. Vannucchi MG, Corsani L, Bani D, Faussone-Pellegrini MS. Myenteric neurons and interstitial cells of cajal of mouse colon express several nitric oxide synthase isoforms. Neurosci. Lett. 2002 326 : 191 195.
74. Weyden LV, Adams DJ, Bradley A. Tools for targeted manipulation of the mouse genome. Physiol. Genomics 2002 11 : 133 164.
75. Anderson TJ, Uehata A, Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 1995 26 : 1235 1241.
76. Morrison SF. Differential control of sympathetic outflow. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001 281 : R683 98.
77. Esler MD, Eikelis N, Lambert E, Straznicky N. Neural mechanisms and management of obesity-related hypertension. Curr. Cardiol. Rep. 2008 10 : 456 463.
78. Fu Q, Zhang R, Witkowski S et al. Persistent sympathetic activation during chronic antihypertensive therapy. A potential mechanism for long-term morbidity?. Hypertension 2005 45 : 1 9.
79. Smolich JJ, Weissberg PL, Friberg P, Broughton A, Korner PI. Left ventricular blood flow during aortic pressure reduction in hypertensive dogs. Hypertension 1991 18 : 665 673.
80. Kimura Y, Hirooka Y, Sagara Y, Sunagawa K. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. ClExp. Hypertens. 2007 29 : 13 21.
81. Weder A. Evolution and hypertension. Hypertension 2007 49 : 260 265.
82. Young JH, Chang YC, Kim JD et al. Differential susceptibility to hypertension is due to selection during the out-of-Africa expansion. PLoS Genet. 2005 1 : e82.
83. Landsberg L. A teleological view of obesity, diabetes and hypertension. ClExp. Pharmacol. Physiol. 2006 33 : 863 867.
84. Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge: Quantitative assessment in human hypertensive disease. Circulation 1999 100 : 1305 1310.
85. Lambert E, Straznicky N, Schlaich M et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 2007 50 : 862 868.
86. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1998 14 : 177 183.
87. Joyner MJ, Charkoudian N, Wallin BG. A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp. Physiol. 2008 93 : 715 724.
88. Barrett CJ, Ramchandra R, Guild SJ, Lala A, Budgett DM, Malpas SC. What sets the long-term level of renal sympathetic nerve activity. A role for angiotensin II and baroreflexes? Circ. Res. 2003 92 : 1330 1336.